8-K: P3 Health Partners Reports Strong Q2, Boosts EBITDA Guidance

P3 Health Partners announced robust second quarter 2026 financial results, including a significant increase in Adjusted EBITDA and an upward revision of full-year guidance.

Summary

• P3 Health Partners reported financial results for the three and six months ended June 30, 2026.
• The company achieved $54.4 million in Adjusted EBITDA for Q2 2026, a substantial improvement from a loss of $17.1 million in the prior year quarter.
• Total revenue for Q2 2026 was $386 million, a 9% increase year-over-year.
• Net income for Q2 2026 was $15.7 million, a significant turnaround from a net loss of $43.7 million in Q2 2025.
• The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $80 million to $110 million.
• At-risk membership was approximately 105,000 for Q2 2026, a 10% decrease year-over-year due to intentional network rationalization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the company showing significant improvement in profitability and raising its full-year guidance, indicating a strong operational turnaround.

Positives

• Significant improvement in Adjusted EBITDA, reaching $54.4 million in Q2 2026 compared to a loss of $17.1 million in Q2 2025.
• Net income turned positive at $15.7 million in Q2 2026, a substantial recovery from a net loss of $43.7 million in the prior year.
• Total revenue increased by 9% to $386 million in Q2 2026 compared to the prior year quarter.
• Raised full-year 2026 Adjusted EBITDA guidance to $80-$110 million.
• Medical margin improved significantly to $97.8 million in Q2 2026 from $30.6 million in Q2 2025.
• Per-member capitated revenue increased by 15% year-over-year, driven by improved network economics and performance.

Negatives

• At-risk membership decreased by 10% to approximately 105,000 members in Q2 2026 compared to the prior year, attributed to intentional network and payer rationalization.

Risks

• Potential need to raise additional capital to fund existing operations or expand services.
• Ability to achieve or maintain profitability.
• Compliance with debt covenants and potential requirement for non-cash charges for goodwill impairment.
• Changes in market conditions, regulatory environment, and competitive landscape.
• Ability to maintain relationships with health plans and other key payors.
• Impact of fluctuations in risk adjustments.
• Increased labor costs and medical expenses.
• Ability to recruit and retain qualified team members and independent physicians.

Future Outlook

The company has raised its full-year 2026 Adjusted EBITDA guidance to a range of $80 million to $110 million, reflecting first-half performance and favorable settlements. The guidance for at-risk members is between 102,000 and 106,000, total revenues between $1.5 billion and $1.6 billion, and medical margin between $260 million and $300 million.

Management Comments

• "Q2 demonstrates that the business is now executing according to our plan. We delivered $54 million of adjusted EBITDA, with the core business driving improved profitability quarter over quarter."
• "Our results reflect the structural improvements now embedded across our contracts, our network, and our operating model, the work I outlined at the onset of my tenure."
• "That strength gives us the confidence to raise our full-year 2026 adjusted EBITDA outlook and to enter the second half focused on execution."

Industry Context

StockSavvy.ai notes that P3 Health Partners' results align with a broader trend in the population health management sector where companies are focusing on profitability and operational efficiency after periods of rapid expansion. The intentional reduction in at-risk membership suggests a strategic shift towards higher-margin contracts.

Stakeholder Impact

• Shareholders: Positive impact expected from improved financial performance and raised guidance, potentially leading to increased stock value.
• Providers: Continued support through value-based care coordination and administrative services, aiming for improved patient outcomes and lower costs.
• Patients: Enhanced patient experience through coordinated and integrated care navigation.
• Payors: Improved network economics and performance contributing to better contract terms.

Next Steps

• Management to host a conference call and webcast on August 10, 2026, at 4:30 PM ET to discuss Q2 2026 results.
• Focus on execution in the second half of 2026.
• Continue to embed structural improvements across contracts, network, and operating model.

Key Dates

Recommendation

The company has demonstrated a significant operational turnaround with improved profitability and raised guidance, which is positive. However, the decrease in at-risk membership and ongoing risks related to capital needs and market conditions warrant a cautious approach. A 'hold' recommendation reflects the positive momentum while acknowledging the inherent uncertainties in the healthcare sector and the company's specific challenges.

Keywords

Population Health Management, Adjusted EBITDA, Medical Margin, Capitated Revenue, At-risk Membership, Healthcare Services, Financial Results, Guidance